SYS6010+SG001
Small molecule
SYS6010+SG001 is one of 47 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
46
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
241 competitors in Esophageal Squamous Cell Carcinoma
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Imfinzi
AstraZenecaPhase 3
Eloxatin
TevaPhase 3
Tecentriq
RochePhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Taxotere
AAvyxa
Phase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SYS6010+SG001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]